BMO Capital raised the firm’s price target on Gilead (GILD) to $102 from $94 and keeps an Outperform rating on the shares. The firm cites a “consistent steady performance” from Gilead this quarter, which continues to show the reliable strength in its HIV business, the analyst tells investors in a research note. This is encouraging ahead of the company’s U.S. filing of lenacapavir for PrEP, BMO added.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD: